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Background: Carotid intima-media thickness (CIMT) and carotid atherosclerotic plaque (CAP) are well-known
indicators of atherosclerosis. However, few studies have reported the value of CIMT and CAP for predicting renal
artery stenosis (RAS). We investigated the predictive value of CIMT and CAP for RAS and propose a model for
predicting significant RAS in patients undergoing coronary angiography (CAG).
Methods: Consecutive patients who underwent renal angiography at the time of CAG in a single center in 2011
were included. RAS ≥50% was considered significant. Multiple logistic regression analysis with step-down variable
selection method was used to select the best model for predicting significant RAS and bootstrap resampling was
used to validate the best model. A scoring system for predicting significant RAS was developed by adding the
closest integers proportional to the coefficients of the regression formula.
Results: Significant RAS was observed in 60 of 641 patients (9.6%) who underwent CAG. Hypertension, diabetes,
significant coronary artery disease (CAD) and chronic kidney disease (CKD) stage ≥3 were more prevalent in
patients with significant RAS. Mean age, CIMT and number of anti-hypertensive medications (AHM) were higher
and body mass index (BMI) and total cholesterol level were lower in patients with significant RAS. Multiple logistic
regression analysis identified significant CAD (odds ratio (OR) 5.6), unilateral CAP (OR 2.6), bilateral CAP (OR 4.9), CKD
stage ≥3 (OR 4.8), four or more AHM (OR 4.8), CIMT (OR 2.3), age ≥67 years (OR 2.3) and BMI <22 kg/m2 (OR 2.4) as
independent predictors of significant RAS. The scoring system for predicting significant RAS, which included these
predictors, had a sensitivity of 83.3% and specificity of 81.6%. The predicted frequency of the scoring system agreed
well with the observed frequency of significant RAS (coefficient of determination r2 = 0.957).
Conclusions: CIMT and CAP are independent predictors of significant RAS. The proposed scoring system, which
includes CIMT and CAP, may be useful for predicting significant RAS in patients undergoing CAG.
Keywords: Renal artery stenosis, Coronary artery disease, Carotid atherosclerotic plaque, Carotid intima-media
thickness, Prediction modelBackground
Renal artery stenosis (RAS) increases the risk of mortal-
ity in patients with cardiovascular disease. RAS is associ-
ated with the prevalence and severity of coronary artery
disease (CAD) [1-3], and is a correctable cause of severe
hypertension and ischemic nephropathy [4]. However,
RAS remains under-recognized, because most patients
with RAS have no symptoms or signs. RAS is more* Correspondence: saint536@hanmail.net
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reproduction in any medium, provided the orprevalent in patients undergoing coronary angiography
(CAG) than in the general population [5]. Performing
renal angiography at the time of CAG can be a safe,
cost-effective diagnostic strategy in patients at high risk
of significant RAS [6]. However, routine evaluation for
RAS in asymptomatic patients undergoing CAG is diffi-
cult to justify, because of the lack of evidence for clinical
benefits associated with renal artery intervention in
patients with RAS. An advisory from American Heart
Association for renal angiography at the time of CAG
focuses on occasional cases with symptoms or clues. This is an Open Access article distributed under the terms of the Creative
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RAS at the time of CAG in asymptomatic patients have
not been established.
Carotid intima-media thickness (CIMT) and carotid
atherosclerotic plaque (CAP) are well-known indicators
of systemic atherosclerosis [7,8]. Although several stud-
ies have proposed models for predicting significant RAS
using clinical parameters such as CAD, age, peripheral
artery disease (PAD), and kidney function in patients
undergoing CAG [9-11], no studies have reported the
value of ultrasonography measurements of CIMT or
CAP for predicting RAS. The aims of this study were
to determine whether CIMT and CAP can predict
RAS, and to propose a prediction model for RAS using
these carotid ultrasonography measurements in patients
undergoing CAG.
Methods
Study subjects and baseline data collection
From January to December 2011, consecutive patients
undergoing elective CAG at Hanyang University Guri
Hospital were prospectively included in this study. Patients
with end-stage renal disease, patients undergoing emer-
gency percutaneous coronary intervention (PCI), and pa-
tients with a history of renal artery intervention were
excluded. Written informed consent was obtained from all
patients at the time of enrollment in the study. All patients
underwent simultaneous coronary and renal angiography.
They also completed physical examinations including
measurement of blood pressure, body weight and height,
and laboratory tests including serum creatinine level, lipid
profiles, hemoglobin A1c level and urinalysis. Body mass
index (BMI) was calculated as (weight)/(height)2 (kg/m2).
Proteinuria was defined as a random urine protein/creatin-
ine ratio of >300 mg/g. The estimated glomerular filtration
rate (eGFR) was calculated using the Modification of Diet
in Renal Diseases equation. The classification of chronic
kidney disease (CKD) stages stated in Kidney Disease Out-
comes Quality Initiative guidelines was used to define renal
function impairment [12]. Carotid ultrasonography was
performed to measure CIMT and CAP. The institutional
review board of Hanyang University Guri Hospital ap-
proved the study design and procedures.
Carotid ultrasonography measurements
CIMT was measured from the lower arterial wall on longi-
tudinal views of each distal common carotid artery during
end-systole. The measurement of CIMT was achieved
using automated software (Philips Healthcare, Andover,
MA, USA). The average value of the right- and left-sided
CIMTs was used for analysis. CAP was defined as the pres-
ence of an area with a ≥50% increase in the intima-media
thickness compared to that of the neighboring vessel wall.
CAP was sought and identified in both common carotidarteries on transverse views, and was measured on longitu-
dinal views.
Coronary and renal angiography
The standard approach for CAG in the hospital where
this study was performed is femoral, and right radial
approach is used in a minority of patients if the femoral
approach is not available or the patients specially request
the radial approach. The femoral artery approach was
used for both the coronary and simultaneous renal
angiography in this study. 5-Fr Judkins left and right
diagnostic catheters (Cordis, Bridgewater, NJ, USA) were
used for left and right coronary angiography, respect-
ively. Renal angiography was performed using a 5-Fr
Judkins right diagnostic catheter engaged in or directed
to the renal artery ostium, with contrast medium flowing
back from the renal artery. Both renal arteries were
visualized in anterior-posterior projections. The degree
of stenosis was measured using quantitative coronary
angiography software (Siemens, Philadelphia, PA, USA).
Significant CAD was defined as stenosis ≥70% in at least
one coronary artery. Significant RAS was defined as
stenosis ≥50% in at least one side.
Statistical analysis
The subjects were divided into two groups according
to the presence or absence of significant RAS. The stu-
dent’s t test was used to compare continuous variables
such as age, BMI, total cholesterol level and eGFR be-
tween the two groups. Variables with skewed distribu-
tions such as triglyceride level, high density lipoprotein
(HDL) cholesterol level and CIMT were compared using
Mann–Whitney U test. The χ2 test was used to compare
binary variables such as hypertension, gender, diabetes,
smoking, significant CAD, presence of CAP and CKD
stage ≥3.
The model for predicting significant RAS was devel-
oped as following; the best-fit model predicting for
significant RAS was determined using multiple logistic
regression analysis, the model was validated to identify
the degrees of optimism and variance, and finally, a scor-
ing system for predicting significant RAS was developed
using the coefficients from the regression formula of the
best-fit model.
In order to find the best-fit model, we transformed the
continuous variables into binary variables using the
Youden index-J of the receiver operating characteristic
(ROC) curve to maximize their discriminative powers of
the best-fit model (e.g., age ≥67 years, BMI <22 kg/m2).
Although dichotomization of continuous variables may
cause bias and weaken the discriminative power of the
model, we used this method because a model using
binary or categorical variables would be more accessible
than a model using continuous variables. The extent of
Figure 1 Flowchart of the patients enrolled in the study.
*eGFR <15 ml/min/1.73 m2. † 8 cases without carotid
ultrasonography results, 13 cases without data for height or body
weight and 16 cases without laboratory data. CAG, coronary
angiography; eGFR, estimated glomerular filtration rate calculated
using the Modification of Diet in Renal Diseases equation; PCI,
percutaneous coronary intervention; CIMT, carotid intima-media
thickness; CA, carotid atherosclerotic plaque.
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eral, bilateral). Then, multiple logistic regression analysis
was performed with all binary variables available and the
extent of CAP as a categorical variable, to reduce biases
in variable selection. Backward variable selection using
Wald statistics was performed to identify significant
variables and reduce the best-fit model to acceptable
events per variable [13]. The exclusion criterion for the
backward selection process was set at p ≥ 0.10, to avoid
excluding modestly significant variables.
Next, validation and calibration of the best-fit model
were performed using bootstrapping methods. Bootstrap
re-sampling is an effective technique for internal valid-
ation and calibration of a prediction model [14]. Valid-
ation using bootstrap re-sampling would estimate the
likely performance of the model on a new sample of
patients from a same clinical setting. Calibration would
measure the degree of error between the predictive
probability and observed probability of the model. The
validation was performed with 1,000 re-samples drawn
using the 0.632 bootstrap technique [15]. We programed
the statistical software to calculate new optimal cut-off
points for continuous variables, generate binary variables
using the new cut-off values in each bootstrap sample
and run a multiple logistic regression analysis using the
backward selection method with all the new binary vari-
ables. Bootstrap models were built from each bootstrap
sample. The estimate of optimism in the best-fit model










where O is the estimate of optimism, Coriginal sample is
the area under the curve (AUC) of the ROC curve of the
bootstrap model in the original data, Cbootstrap sample is
the AUC of the ROC curve of the bootstrap model in
each bootstrap sample and M is the number of boot-
strap samples.
Finally, using the best-fit model, we developed a risk
scoring system for predicting significant RAS. Using the




1−Pð Þ ¼ αþ β1X1 þ β2X2 þ β3X3…þ βnXn
when coefficient β1 < β2 < β3 < … < βn
 
we assigned the integer closest to βn/β1 as the score for
the variable Xn. Then, we summated the integers to gen-
erate a risk score for predicting significant RAS in each
patient, if variable Xn was present in the patient. ROC
curve analysis was performed to evaluate the discrimina-
tive power and optimal cut-off point of the scores forpredicting significant RAS. The goodness-of-fit of the
risk scoring system for significant RAS was assessed
using the Hosmer-Lemeshow test and Levenburg-
Marquardt nonlinear regression analysis. The predicted




(when L = α + coefficient β × (risk score) in a logistic re-
gression analysis)
All statistical analyses were performed with statistical
software, R-3.0.1 for Windows. The rms package was
used for logistic regression analysis and the ROCR,
pROC and Epi packages were used to identify the opti-
mal cut-off points for continuous variables and automat-
ically transform the continuous variables into binary
variables.
Results
Baseline characteristics of subjects
Of the 1141 patients who underwent CAG during the
period of study, 641 patients remained for the final analysis
(Figure 1). The mean age was 61.2 ± 12.5 years and 49% of
the patients were male. Hypertension was present in 61.0%
of patients, diabetes in 27.8%, and smoking in 27% of the
patients. The number of anti-hypertensive medications
(AHM) taken by a patient was 1.6 ± 1.0. The mean serum
creatinine was 0.87 ± 0.37 mg/dl, and CKD stage ≥3 was
present in 45 patients (7%). Total cholesterol level was
175.8 ± 41.1 mg/dl, HDL cholesterol level 47.3 ± 12.5 mg/dl
and triglyceride level 148.6 ± 120.9 mg/dl. The mean CIMT
was 0.89 ± 0.26 mm and CAP was present in 271 patients
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and significant RAS in 60 patients (9.4%). The baseline
characteristics of patients with and without significant RAS
are shown in Table 1. The mean age, number of AHM and
CIMT were higher in patients with significant RAS than
those without significant RAS, whereas BMI, total choles-
terol level, HDL cholesterol level and eGFR were lower in
patients with significant RAS than those without significant
RAS. Triglyceride level was not different between the two
groups. Hypertension, diabetes, CKD stage ≥3 and protein-
uria were more prevalent in patients with significant RAS
than those without significant RAS, whereas the propor-
tions of males and current smokers were not different be-
tween the two groups. Significant CAD and the presence of
CAP were more prevalent in patients with significant RAS
than those without significant RAS.
Multiple logistic regression analysis for predictors of
significant RAS
The optimal cut-off values for continuous variables
obtained by ROC curve analysis were CIMT 1.0 mm
(AUC= 0.683, p = 0.002), age 67 years (AUC= 0.726,
p <0.001), BMI 22 kg/m2 (AUC= 0.608, p = 0.003), total
cholesterol level 158 mg/dl (AUC = 0.618, p = 0.002),
HDL cholesterol level 47 mg/dl (AUC = 0.577,
p = 0.128) and triglyceride level 119 mg/dl (AUC =
0.537, p = 0.323). Multiple logistic regression analysis
including with all the binary and categorical variablesTable 1 Baseline characteristics of patients undergoing coron
Without RAS ≥ 50% (n = 581)
Age (years) 60.3 ± 12.4
Male gender, n (%) 282 (48.5)
Hypertension, n (%) 348 (59.9)
Number of AHM 1.5 ± 1.1
Diabetes, n (%) 152 (26.2)
Smoking, n (%) 155 (26.7)
BMI (kg/m2) 25.5 ± 3.4
Total Cholesterol (mg/dl) 177.5 ± 40.9
HDL Cholesterol (mg/dl)† 46.0 (39.0, 55.0)
Triglyceride (mg/dl)† 122.0 (89.0, 173.0)
eGFR (ml/min/1.73 m2) 111.5 ± 35.1
CKD stage ≥3 n (%) 27 (4.6)
Proteinuria, n (%) 76 (13.1)
Significant CAD*, n (%) 124 (21.3)
CIMT (mm)† 0.84 (0.72, 0.98)
CAP, n (%) 221 (38)
Results are shown as the mean ± SD or n (%).
The percentage inside the brackets indicates either the percentage in the group wi
*CAD with stenosis ≥70% at least one coronary artery.
†Data for skewed variables are shown as the median (1st quartile, 3rd quartile).
RAS, renal artery stenosis; AHM, anti-hypertensive medications; BMI, body mass ind
CKD, chronic kidney disease; CAD, coronary artery disease; CIMT, carotid intima-medidentified significant CAD (odds ratio (OR) 5.8,
p <0.001), CKD stage ≥3 (OR 4.3, p = 0.002), four or
more AHM (OR 3.6, p = 0.039), BMI ≥22 kg/m2 (OR
2.6, p = 0.014), CIMT ≥1.0 mm (OR 2.2, p = 0.020), uni-
lateral CAP (OR 2.9, p = 0.039) and bilateral CAP (OR
5.5, p <0.001) as significant predictors of significant
RAS (Figure 2). Among the significant predictors,
significant CAD, CKD stage ≥3, four or more AHM
and bilateral CAP were stronger predictors of signifi-
cant RAS. Age ≥67 years and HDL cholesterol level
≥47 mg/dl were marginally significant predictors of
significant RAS. Total cholesterol level ≥158 mg/dl,
hypertension, male gender, current smoking, diabetes,
proteinuria and triglyceride level ≥119 mg/dl were not
significant predictors of significant RAS. The average
variable inflation factor of all the variables included in
the multiple logistic regression analysis was 1.19 and no
variable inflation factor of any variable exceeded 1.4. In
multiple logistic regression analysis with backward selec-
tion, significant CAD, unilateral or bilateral CAP, CKD
stage ≥3, four or more AHM, CIMT ≥1.0 mm, age ≥67 years
and BMI < 22 kg/m2 remained as predictors of significant
RAS (Table 2).
Scoring system for significant RAS
Using the results of the multiple logistic regression
analysis with backward selection, we developed a scoring
system for predicting significant RAS (Table 3). Toary angiography
With RAS ≥ 50% (n = 60) P-value
70 ± 9.1 < 0.001
32 (53.3) 0.479
43 (71.7) 0.049
2.2 ± 1.1 < 0.001
26 (43.3) 0.005
18 (30) 0.581
24.1 ± 4.3 0.006
159.7 ± 39 0.003
42.5 (38.0, 51.5) 0.049
115.5 (81.3, 159.0) 0.343
81.5 ± 34.7 < 0.001
18 (30) < 0.001
15 (25) 0.012
44 (73.3) < 0.001
1.00 (0.85, 1.15) < 0.001
50 (83.3) < 0.001
th RAS ≥50% or the percentage in the group without RAS ≥50%.
ex; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate;
ia thickness; CAP, the presence of carotid atherosclerotic plaque.
Figure 2 Predictors of RAS ≥50%. The odds ratio and CI are derived from multiple logistic regression analysis including all variables. The ruler is
transformed into a log-scale. Triangles indicate OR, black bars 90% CI and grey bars 95% CI. Numbers inside the brackets indicate the optimal
cut-off points for the continuous variables, derived from the Youden index-J of ROC curve analysis. Significant CAD, CKD stage ≥3, four or more
AHM, CAP, CIMT ≥1.0 mm, BMI <22 kg/m2 and Age ≥67 years are significant predictor for RAS ≥50%. CAD, coronary artery disease; CKD, chronic
kidney disease; AHM, anti-hypertensive medication; BMI, body mass index; HDL, high density lipoprotein; CIMT, carotid intima-media thickness;
CAP, carotid atherosclerotic plaque; RAS, renal artery stenosis, CI, confidence interval.
Table 3 Scoring system for predicting RAS ≥50%
Predictor Criteria Score*
CAD No stenosis ≥70% on coronary arteries 0
Stenosis ≥70% on at least one coronary artery 2
CKD Stage <3 0
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tegers proportional to the coefficient β of each predictor.
The smallest coefficient β was 0.831 for age ≥67 years
and the largest one was 1.724 for significant CAD. The
ratios of the coefficients of predictors to the smallest coef-
ficient were therefore all between 1 and 2. We assigned a
score of 1 to unilateral CAP, CIMT ≥1.0 mm, age ≥67 years
and BMI <22 kg/m2, and a score of 2 to significant CAD,
bilateral CAP, CKD stage ≥3 and four or more AHM. The
total scores ranged from 0 to 11. In ROC curve analysis,
the scoring system for significant RAS showed an AUC of
0.896 (95% confidence interval 0.869 - 0.918), which was
not significantly different from the AUC of the best-fit
model (AUC= 0.898, difference = 0.002, p = 0.69 using theTable 2 Multiple logistic regression analysis for
independent predictors of RAS ≥50%
Predictors Coefficient β OR (95% CI) p-value
Significant CAD* 1.724 5.6 (2.9-11.0) <0.0001
Extent of CAP One side 0.958 2.6 (1.0-6.8) 0.0503
Both sides 1.584 4.9 (2.1-11.1) 0.0002
CKD Stage ≥3 1.566 4.8 (2.1-11.0) 0.0002
Four or more AHM 1.563 4.8 (1.5-14.8) 0.0069
CIMT ≥1.0 mm 0.849 2.3 (1.2-4.5) 0.0109
Age≥ 67 years 0.831 2.3 (1.2-4.6) 0.0173
BMI < 22 kg/m2 0.872 2.4 (1.2-4.9) 0.0174
Multiple logistic regression analysis was performed using a backward
selection method.
*Stenosis ≥70% in at least one coronary artery.
OR, odds ratio; CI, confidence interval; CAD, coronary artery disease; AHM,
antihypertensive medications; eGFR, estimated glomerular filtration rate; CIMT,
carotid intima-media thickness; CAP, carotid atherosclerotic plaque.DeLong method). The scoring system showed sensitivity of
83.3% and specificity of 81.6% at a cut-off point of ≥4 Using
the same cut-off point and a prevalence of significant RAS
9.4%, the positive predictive value was 31.8%, and the nega-
tive predictive value was 97.7% (Figure 3). The predicted
frequency of significant RAS using the scoring system
agreed well with the observed frequency of significant RAS.Stage ≥3 2
AHM Less than 4 0
4 or more 2
BMI ≥22 kg/m2 0
<22 kg/m2 1
Age <67 years old 0
≥67 years old 1
CAP None 0
Present at one side 1
Present at both sides 2
CIMT <1.0 mm 0
≥1.0 mm 1
This scoring system should be independently validated, before used in
clinical practice.
*Total scores range from 0 to 11.
CAD, coronary artery disease; CKD, chronic kidney disease; AHM,
anti-hypertensive medication; BMI, body mass index; CIMT, carotid intima-media
thickness; CAP, carotid atherosclerotic plaque.
Figure 3 Performance of the scoring system for predicting
RAS ≥50%. The broken line indicates the ROC curve of the scoring
system and the unbroken line indicates the ROC curve of the best-fit
model. The difference between the two AUCs is 0.002, and is not
significant (p = 0.69, DeLong method). The numbers inside the
brackets indicate the 95% confidence intervals of the AUCs. *The
PPV and NPV are estimated using a 9.4% prevalence of RAS ≥50%.
AUC, area under curve of ROC curve; ROC, receiver operating
characteristics; PPV, positive predictive value; NPV, negative
predictive value.
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scoring system showed p = 0.881, and the coefficient of de-
termination between the predicted frequency and observed
frequency using Levenburg-Marquardt non-linear regres-
sion analysis was R2 = 0.957 (Table 4).Validation and calibration of the best-fit model
The apparent AUC of the best-fit model derived from
multiple logistic regression analysis with backward selec-
tion was 0.898 (95% confidence interval 0.872-0.918).
Validation of the best-fit model with 1000 bootstrap re-
samples showed that the average optimism was 0.023
and the adjusted AUC of the best-fit model was 0.875.
The calibration plots of the best-fit model and the boot-
strap model are shown in Figure 4. The estimates of
both models were slightly non-linear, with the bootstrap
model being slightly more non-linear than the best-fit
model. Both models agreed well with the ideal line when
the predicted probability of significant RAS was low, but
the disagreement of the bootstrap model increased with
increasing the predicted probability of significant RAS.
However, the mean absolute error and 0.9 quantile abso-
lute error of the predicted probability were 0.028 and0.047 respectively, suggesting only a small degree of bias
from overfitting in the best-fit model.Discussion
Main findings
We found that the extents of CAP and CIMT were inde-
pendent predictors of significant RAS in patients under-
going CAG. The prevalence of significant RAS increased
with the presence of CIMT and the extent of CAP. The
model for predicting significant RAS which included
significant CAD, CKD stage ≥3, four or more AHM,
age ≥67 years, BMI <22 kg/m2, CIMT ≥1.0 mm, and the
extent of CAP showed a high discrimination power and
a small degree of bias. The predictive frequency of the
scoring system agreed well with the observed frequency
of significant RAS.Prevalence and predictors of significant RAS
The prevalence of significant RAS was 9.4%, which is simi-
lar to the findings of previous studies [3,5,9,11,16,17]. How-
ever, the actual prevalence of significant RAS may be
higher, because we excluded patients undergoing emer-
gency PCI and those with a history of renal artery
intervention.
Hypertension and diabetes, classic risk factors for athero-
sclerosis, were not strongly associated with significant RAS
in this study because they were already reflected by other
predictors, namely significant CAD, CIMT, extent of CAP,
old age, four or more AHM. The high prevalence of hyper-
tension among patients undergoing CAG may also have
contributed to the weak association between significant
RAS and hypertension. Instead, four or more AHM indicat-
ing severe, uncontrolled hypertension was a strong pre-
dictor of significant RAS. The BMI and total cholesterol
levels were paradoxically lower in patients with significant
RAS than those without significant RAS. This may be be-
cause the BMI and total cholesterol level also partially re-
flect muscle mass and nutritional status [18,19]. Patients
with significant RAS often have multiple co-morbidities
and poor general health. Prezewlocki et al. [10] also re-
ported that BMI <25 kg/m2 was a predictor of significant
RAS.
Carotid ultrasonography parameters, such as CAP and
CIMT, are known as the predictors of cardiovascular
disease [7,8,20], and the relationship between RAS and
systemic atherosclerosis is well established [16]. The associ-
ation between CIMT and RAS, however, has only been re-
ported in a few studies [21,22], and the value of the extent
of CAP for predicting RAS has not been reported until
now. This is the first study using a multiple logistic regres-
sion model to report CIMT and the extent of CAP mea-
sured by carotid ultrasonography as independent predictors
of significant RAS in patients undergoing CAG.
Table 4 Observed and predicted frequencies of RAS ≥ 50% using the scoring system
Without RAS ≥50% With RAS ≥50%
Score Numbers of patients (n) Observed frequency (n) Predicted frequency (n) Observed frequency (n) Predicted frequency* (n)
0 156 155 155.12 1 0.88
1 145 144 144.17 1 1.83
2 106 104 103.01 2 2.99
3 77 71 72.26 6 4.74
4 56 48 48.75 8 7.24
5 45 34 33.68 11 11.32
6 28 14 15.90 14 12.10
7 21 9 7.71 12 13.29
8 7 2 1.43 5 5.57
9 0 0 0 0 0
10 0 0 0 0 0
11 0 0 0 0 0
*(Number of patients) × 1/[1 + Exp(-L)], when L = −5.175 + 0.817 × (score).
p = 0.881, Hosmer-Lemeshow test.
Coefficient of determination R2 = 0.957 for agreement with the observed frequency, Levenburg-Marquardt non-linear regression method.
Figure 4 Calibration plot for the model for predicting RAS ≥50%.
The plot illustrates the accuracy of the best-fit model (“Apparent”)
and the bootstrap model (“Bias-corrected”) for predicting RAS
≥50%. Locally weighted scatterplot smoothing was used to
illustrate the relationships of the two models with the ideal line.
Both plots are slightly non-linear and agree well in low predicted
probabilities of RAS ≥50%, but the disagreement between the two
plots grows with the predicted probability of RAS ≥50%. The 0.9
quantile absolute error of the predicted probability is 0.047. The
black dots illustrate the relationship between the predicted
probability and observed probability of the scoring system for
predicting RAS ≥50% in the original data set. The r2 of linear
regression of the dots is 0.982.
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RAS contributes to severe but correctable, hypertension
and to left ventricular hypertrophy. Although RAS is an
independent risk factor for cardiovascular mortality,
screening for RAS in asymptomatic patients is currently
controversial, because none of the large randomized tri-
als to date have shown clinical benefits associated with
renal artery stenting compared with medical therapy in
patients with RAS [23,24]. Routine “drive-by” renal angi-
ography in all patients undergoing elective CAG is espe-
cially difficult to support because of the lack of evidence
of benefit and the low prevalence of RAS. A distinction
should be made, however, between identifying patients
with significant RAS and selecting patients for renal ar-
tery intervention. It is important to identify patients with
significant RAS who are at increased risk of cardiovascu-
lar events and require close observation [25]. RAS is an
independent predictor of mortality in patients with car-
diovascular disease [1,2,25]. From this point of view, it
may be useful to determine indications for performing
renal angiography at the time of CAG in selected pa-
tients undergoing CAG.
The American Heart Association advises renal angiog-
raphy at the time of CAG in patient with multi-vessel
CAD or PAD [6]. The reported prevalence of significant
RAS ranges from 10% to 36% in patients with triple-
vessel CAD [3,9-11,22] and from 21% to 55% in patients
with PAD [9,11,25]. Models for predicting significant
RAS that include multiple clinical predictors may enable
more accurate selection of patients for renal angiog-
raphy. Several studies have proposed prediction models
for significant RAS in patients undergoing CAG [9-11].
Clinical predictors including age, hypertension, BMI,
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eGFR have been used in these models. However, these
prediction models were either too complicated or did
not provide a sufficiently predictive performance to be
applied to clinical practice.
Duplex ultrasonography is a safe and acute non-invasive
screening tool for RAS. The sensitivity and specificity of
duplex ultrasonography were already 92.5% and 95.7%,
respectively, in a 1997 study of patients suspected to have
RAS [26]. Duplex ultrasonography will be a superior
screening modality to any clinical predictors or scoring
methods, if a patient is suspected to have RAS. Neverthe-
less, a scoring system for predicting RAS can still be a
useful tool for clinicians to estimate the risk of RAS in
asymptomatic patients undergoing CAG.
Carotid ultrasonography is a simple, non-invasive tool
frequently used in current clinical practice to evaluate car-
diovascular risk [27]. Our scoring system for predicting sig-
nificant RAS included CIMTand CAP measured by carotid
ultrasonography, and showed better sensitivity and specifi-
city than scoring systems in the previous studies. The high
negative predictive value and moderate positive predictive
value may enable use of the scoring system as a quick
decision-making tool for a physician to undertake a definite
diagnostic testing for significant RAS. The goodness-of-fit
between the predicted and observed frequency of signifi-
cant RAS was high in our model. The scoring system was
also made as simple as possible, so that it could easily be
applied to clinical practice. All the items of the scoring sys-
tem were assigned in the simplest integers, 1 or 2, and the
score range was 0 to11.
We also validated our model with bootstrap re-sampling
technique. Validation and calibration procedures are re-
quired for a prediction model to be useful in clinical prac-
tice. Przewlocki et al. [10] performed validation of their
model by random splitting of the data. However, other pre-
vious studies that reported models for predicting RAS did
not perform validation procedures. Bootstrap re-sampling
is a more effective technique for validating a prediction
model than data splitting [14], and the 0.632 bootstrap
technique used in our validation procedures is a variant
bootstrap method that can provide very similar validation
to that obtained using an independent data set [26]. A small
degree of optimism was observed, and the disagreement in
validation and calibration between the predicted probability
and actual probability increased with increasing predicted
probability. However, the bias from overfitting was accept-
able in this study. We believe that our prediction model
can be a useful tool for evaluating the risk of significant
RAS in patients undergoing CAG.
Limitations
Our study was performed in a single center and may
therefore contain referral bias. Although the patients wereincluded consecutively in the study, the exclusion of
patients because of radial approach, emergency PCI, end-
stage renal disease, previous renal artery intervention, or in-
adequately performed renal angiography may have affected
the recorded prevalence of significant RAS. Carotid ultra-
sonography is a simple and non-invasive tool for assessing
the extent of atherosclerotic diseases, but, is still not per-
formed routinely in patients undergoing CAG. Although
the scoring system can be used for pre-procedural estima-
tion of the probability of RAS, the indications for renal
artery intervention in asymptomatic patients still need to
be established for the prediction model to be relevant to
improving clinical outcomes. Finally, although we validated
our model, internally with bootstrap re-sampling technique,
the proposed scoring system should be externally validated
before being used in routine clinical practice.Conclusions
CIMT and CAP measured by carotid ultrasonography
are independent predictors of significant RAS in patients
undergoing CAG. The proposed model for predicting
significant RAS which includes the carotid ultrasonog-
raphy parameters and other independent predictors
showed good diagnostic performance and only a small
amount of bias, and may be a useful tool for deciding
whether a definite diagnostic procedure is needed at the
time of CAG. Further investigation is needed for inde-
pendent validation of our model.
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